New upcoming Optibodies™!
Press Release | Nordic Biosite AB
FEBRUARY 15, 2017
Täby, Sweden: – We are proudly presenting our new upcoming Optibodies™! Ten new Optibody members, six rabbit and four mouse monoclonal Optibodies are carefully optimized according to criteria of optimal staining pattern. We would like to highlight two very interesting rabbit monoclonal OptibodiesTM; CD79a (BSR20) and CK20 (BSR7). CD79a is an excellent marker for B-cell neoplasia together with CD20. Our BS20 clone offers excellent performance with high signal to noise ratio.
CK20 is a marker of colon carcinomas. Our rabbit monoclonal BSR7 clone offers great staining pattern and intensive staining in colorectal carcinoma cells. Test our CD79a and CK20 Optibodies™, as well as our other antibodies from our OptibodiesTM portfolio.
Our other upcoming OptibodiesTM are: CD2 (BS60), CD4 (BSR4), CD8 (BSR5), CD38 (BSR7), CD43 (BS62), beta catenin (BS31), Glutamine synthetase (BS51), and Cytokeratin 8 (BSR15). These antibodies offer great signal to noise ratio with intensive and specific staining, and they are a very welcome supplement in our Optibody™ collection.
Jenny Wiklund, Marketing Coordinator, Nordic BioSite AB
Tel: +46 (0) 854 443 341
Mobile: +46 (0) 709 35 95 57
Click on New upcoming Optibodies™! for more information.
Click on Nordic Biosite to contact the company directly.
Read more from our web site: http://www.nordicbiosite.com/sites/default/files/optibodiesnew.pdf
Supplier: Nordic Biosite
Address: Propellervägen 4A, 183 62 Täby, Sweden
Tel: +46 (0)8 544 433 40
Fax: +46 (0)8 756 94 90